NEW YORK, NY / ACCESSWIRE / December 20, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Endo International plc (“Endo” or the “Company”) (NASDAQ: ENDP) and certain of its officers. The class action, filed in United States District Court, for the Eastern District of Pennsylvania, and docketed under 17-cv-05114, is on behalf of a class consisting of investors who purchased or otherwise acquired Endo securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Endo securities between September 28, 2015, and February 28, 2017, both dates inclusive, you have until January 16, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and amount of shares purchased.

[Click here to join this class action]

Endo International plc provides specialty healthcare solutions. The Company develops, manufactures, markets, and distributes pharmaceutical products and generic drugs. Endo International offers its products to the medical and healthcare industries around the globe.

On September 28, 2015, Endo announced that it had completed its $8.05 billion acquisition of Par Pharmaceutical Holdings, Inc. (“Par Pharmaceutical”) from the private investment firm TPG (the “Par Pharmaceutical Acquisition”). Par Pharmaceutical Companies Inc. is a manufacturer and distributor of generic drugs and operates as a subsidiary of Par Pharmaceutical.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Par Pharmaceutical had colluded with several of its industry peers to fix generic drug prices; (ii) the foregoing conduct constituted a violation of federal antitrust laws; (iii) the competitive advantages of the Par Pharmaceutical Acquisition, which Endo touted to its shareholders as, inter alia, “a compelling opportunity to drive future double-digit growth, serve our customers and build shareholder value,” were in fact derived in part from Par Pharmaceutical’s illegal conduct and thus unsustainable; (iv) for the same reasons, the “impressive track record of delivering strong operating results” that Endo attributed to former Par Pharmaceutical executive Paul Campanelli in announcing his promotion to Endo’s CEO consisted in part of illegal conduct; (v) for the foregoing reasons, Endo’s revenues during the Class Period were in part the result of illegal conduct and likewise unsustainable; and (vi) as a result of the foregoing, Endo’s public statements were materially false and misleading at all relevant times.

On November 3, 2016, media outlets reported that U.S. prosecutors were considering filing criminal charges by the end of 2016 against Par Pharmaceutical and several other pharmaceutical companies for unlawfully colluding to fix generic drug prices in an article titled, “U.S. Charges in Generic-Drug Probe to Be Filed by Year-End.”

On this news, Endo’s share price fell $3.54, or 19.48%, to close at $14.63 on November 3, 2016.

On March 1, 2017, Endo filed an Annual Report on Form 10-K with the SEC, reporting in full the Company’s financial and operating results for the quarter and year ended December 31, 2016. Reflecting the extent to which Par Pharmaceutical’s unlawful conduct had previously inflated Endo’s revenues, the Company reported a net loss of $3.35 billion, or $15.03 per diluted share, on revenue of $4.01 billion, citing, in part, a 27% increase in cost of revenues and a decrease in gross margins from 36% in 2015 to 34% in 2016.

On this news, Endo’s share price fell $0.83, or 6.08%, to close at $12.82 on March 1, 2017.

On October 31, 2017, attorneys general from 46 states and the District of Columbia amended their antitrust case on generic drug price-fixing conspiracy against the $75 billion generic drug industry to add 18 new companies, including Endo’s wholly-owned subsidiary, Par Pharmaceutical Companies, Inc. The states allege these companies violated antitrust laws to artificially inflate the prices of the drugs by agreeing to “collectively raise and/or maintain prices for a particular generic drug,” and agreeing to divvy up the market for the drugs to reduce competition by “refusing to bid for particular customers or by providing a cover bid that they knew would not be successful.” This in effect “avoided price erosion” and “increased pricing for targeted products without triggering a ‘fight to the bottom’ among existing competitors.”

According to the amended complaint, these companies conspired to unreasonably restrain trade, artificially inflate and reduce competition in the generic pharmaceutical industry for the markets of fifteen generic drugs: Acetazolamide, Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Fosinopril-Hydrochlorothiazide, Glipizide-Metformin, Glyburide, Glyburide-Metformin, Leflunomide, Meprobamate, Nimodipine, Nystatin, Paromomycin, Theophylline, Verapamil and Zoledronic Acid. As a result of the conspiracy, “[p]rices for dozens of generic drugs have risen – while some have skyrocketed, without explanation, sparking outrage from politicians, payers, and consumers across the country whose costs have doubled, tripled, or even increased 1,000% or more.”

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 484708

NEW YORK, NY / ACCESSWIRE / December 20, 2017 / The Klein Law Firm reminds investors that a class action complaint has been filed on behalf of shareholders of Rio Tinto PLC (NYSE: RIO) who purchased shares between October 23, 2012 and February 15, 2013. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.

In 2011, Rio Tinto acquired certain Riversdale Mining Limited coal assets in Mozambique that became known as Rio Tinto Coal Mozambique (“RTCM”). The complaint alleges that, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information regarding RTCM’s true value, including that: (1) within months of the purchase, now-former senior executives knew of material problems adversely affecting RTCM’s multi-billion dollar publicly reported valuation; (2) as time passed, the same senior executives knew of additional problems and events that, under applicable accounting rules, required an impairment analysis of RTCM and reductions in its reported valuation; and (3) these executives thwarted the required impairment analysis and continued to tout RTCM’s value to investors.

Shareholders have until December 22, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the Class Period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/rio-tinto-plc?wire=1.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 484695

NEW YORK, NY / ACCESSWIRE / December 20, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Acorda Therapeutics, Inc. (“Acorda”) (NASDAQ: ACOR) between April 18, 2016 and November 14, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more information, go to:

http://www.zlk.com/plsra-c/acorda-therapeutics-inc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the Class Period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the drug treatment, tozadenant, entailed significant undisclosed safety risks; (ii) accordingly, the Company had overstated tozadenant’s approval prospects and commercial viability; (iii) the Company had likewise overstated the benefits of the Biotie Acquisition; and (iv) as a result of the foregoing, Acorda’s shares traded at artificially inflated prices during the Class Period.

On November 15, 2017, Acorda revealed it had ceased enrolling new patients in its Phase 3 trial of its Parkinson’s treatment due to patient deaths.

If you suffered a loss in Acorda, you have until January 17, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 484696

CALGARY, AB / ACCESSWIRE / December 20, 2017 / Emerald Bay Energy Inc. (TSX-V: EBY) (the ”Corporation” or ”Emerald Bay”) today reported that the Corporation has closed the first tranche of its previously announced private placement. Pursuant to this first closing, an aggregate 16,666,667 units (”Units”) were issued to two (2) subscribers at a price of $0.015 per Unit, for aggregate consideration of $250,000. Each Unit consisted of one (1) Common Share of the Corporation and one (1) share purchase warrant (the ”Warrant”) (each full Warrant shall entitle the holder thereof to purchase one (1) additional Common Share of the Corporation for a period of 12 months from the issuance of the Units at a price of $0.05) (the ”Offering”). The Warrants are subject to an acceleration clause whereby if after four months and one day following the date the Warrants are issued, the closing price of the Common Shares of the Corporation on the principal market on which such shares trade is equal to or exceeds $0.10 for 30 consecutive trading days (with the 30th such trading date hereafter referred to as the ”Eligible Acceleration Date”), the Warrant expiry date shall accelerate to the date which is 30 calendar days following the date a press release is issued by the Corporation announcing the reduced warrant term, provided, no more than five business days following the Eligible Acceleration Date: (i) the press release is issued; and (ii) notices are sent to all warrant holders.

Emerald Bay further reported that it has increased the total private placement/Offering from an aggregate $300,000 (see press release dated November 21, 2017) to an aggregate $400,000. No other terms of the private placement have been altered.

The net proceeds will be used in respect existing drilling commitments on the Corporation’s assets in Texas, specifically in relation to the following:

at the Corporation’s Wooden Horse property, the Corporation: (i) will add lifting equipment to begin production operations on the recently drilled Kuhn 4 well, at an approximate cost of $22,500; (ii) is evaluating locations for two new wells (Kuhn 5 and Kuhn 6) to be drilled as Buda formation targets at an estimated cost of $65,000 each; and (iii) will renew leased acreage and lease acreage adjacent to the Wooden Horse property at an approximate cost of $35,000; and
at the Corporation’s Nash Creek property, the Corporation plans to drill short radius horizontal legs to the fault detected by the 3D seismic in the BeauMar 1 well at an approximate cost of $68,000.

All of the Common Shares and Warrants issued pursuant to the private placement are subject to a 4-month hold period. The terms of the private placement are according to the TSX Venture Exchange Discretionary Waivers of $0.05 Minimum Pricing Requirement Bulletin, dated April 7, 2014, and completion of the private placement is subject to the final approval of the TSX Venture Exchange.

About Emerald Bay

Emerald Bay Energy Inc. (EBY) is an energy company with oil producing properties in southwest Texas as well as non operated oil, natural gas, and electricity generation interests in Central Alberta, Canada. EBY is the operator of the Wooden Horse and Nash Creek Projects in Guadeloupe, Texas, where the Company currently now owns a 50.00% working interest in those projects. The Company also owns 75% of Production Resources Inc., a South Texas oil company.

To stay informed on Emerald Bay Energy, please join our Investor Group at https://www.8020connect.com/groups/emerald-bay-energy-inc for all upcoming news releases, articles, comments and questions.

For further information, please contact:

Emerald Bay President, Shelby D. Beattie, by telephone at (403) 262-6000
Email: info@ebyinc.com
www.ebyinc.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release includes statements that may constitute ”forward-looking” statements, usually containing the words ”believe,” ”estimate,” ”project,” ”expect,” ”plan,” ”intend,” ”anticipates,” ”projects,” ”potential” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Forward-looking statements are statements that are not historical facts.

Information inferred from the interpretation of drilling results may also be deemed to be forward-looking statements, as it constitutes a prediction of what might be found to be present when and if a well is actually developed. BOE’s may be misleading, particularly if used in isolation. A BOE conversion ratio of 6 Mcf: 1 Bbl is based on energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. The reader is cautioned that assumptions used in the preparation of such information, which are considered reasonable by Emerald Bay at the time of preparation, may prove to be incorrect. Actual results achieved will vary from the information provided and the variations may be material. There is no representation by Emerald Bay that actual results achieved will be the same in whole or part as those indicated in the forward-looking statements. Forward-looking statements in this document include statements regarding the Company’s exploration, drilling and development plans, the Company’s expectations regarding the timing and success of such programs. In particular, forward-looking information in this news release includes, but is not limited to, statements with respect to: pipeline acquisitions and leasing; pipeline permits, pipeline construction, production estimates, drilling operations, completion operations, funding and development goals. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, level of activity, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Factors that could cause or contribute to such differences include, but are not limited to, fluctuations in the prices of oil and gas, uncertainties inherent in estimating quantities of oil and gas reserves and projecting future rates of production and timing of development activities, competition, operating risks, acquisition risks, liquidity and capital requirements, the effects of governmental regulation, adverse changes in the market for the Company’s oil and gas production, dependence upon third-party vendors, and other risks detailed in the Company’s periodic report filings with the applicable securities regulators.

SOURCE: Emerald Bay Energy Inc.

ReleaseID: 484709

CEO and Chairman of Golden Boy Promotions Endorses New Product, Skulltec’s Skullcap, to Reduce Likelihood of Chronic Traumatic Encephalopathy (CTE)

LOS ANGELES, CA / ACCESSWIRE / December 20, 2017 / As part of a campaign to reduce the prevalence of CTE and other brain injuries in boxers, former 10-time world champion and current Chairman and CEO of Golden Boy Promotions, Oscar De La Hoya, is teaming up with Skulltec, the new high-performing safety headgear company out of Arizona.

As the diagnosis for Chronic Traumatic Encephalopathy (CTE), better known in the boxing world as Punch Drunk Syndrome, continues to grow, De La Hoya has made a significant investment in Skulltec. Specifically, De La Hoya is endorsing the Skullcap – a safety item designed to go under any headgear used in sparring.

“Fighters put everything on the line every time they step in the ring and, far too often, it results in serious damage,” De La Hoya said. “While head trauma can happen in an instant, far more often the damage comes from repeated punches during a lifetime of fighting and sparring. If I can do anything to help boxers avoid CTE and other brain injuries, I will, and I believe using Skulltec’s Skullcap in sparring will have a positive impact.”

Multiple studies performed have shown that using Skulltec’s products results in a significant reduction in impact, and therefore, it reduces the damage done.

Skulltec is excited to be teaming up with Oscar and Golden Boy Promotions to create a safety-driven culture in the sport of boxing! Protecting any athlete has been and always will be our goal!

Skulltec is only available online at Skulltec.com.

Contacts:

Bob Ferguson, CEO & Founder, 520.840.1961 | info@skulltec.com

Stefan Friedman, Golden Boy Promotions, 646-241-7786

SOURCE: Skulltec LLC

ReleaseID: 484703